Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833960 | 0.89 | MCL1 (0.43) | HIF1APRSS12ALBXDHSLC22A12 | |
| SCHEMBL6834186 | 0.89 | HIF1A (0.49) | HIF1AACLYPRSS12ALBXDH | |
| SCHEMBL6834124 | 0.89 | XDH (0.40) | HIF1APRSS12ALBXDHSLC22A12 | |
| SCHEMBL6834495 | 0.89 | HIF1A (0.41) | HIF1APRSS12ALBCDK2 | |
| SCHEMBL6835617 | 0.88 | CDK2 (0.42) | HIF1APRSS12ALBXDHSLC22A12 | |
| SCHEMBL6931399 | 0.88 | HIF1A (0.39) | HIF1ATHRBPRSS12ALBCDK2 | |
| SCHEMBL6830490 | 0.84 | HIF1A (0.55) | HIF1AALBCDK2 | |
| SCHEMBL6708875 | 0.83 | DHODH (0.37) | HIF1ATHRBF2F10SMN1; SMN2 | |
| SCHEMBL6710362 | 0.82 | F10 (0.36) | HIF1ATHRBF2F10SMN1; SMN2 | |
| SCHEMBL6833249 | 0.82 | MCL1 (0.41) | HIF1APRSS12ALBXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ACMSD 34/4885HIF1A 220/4885THRB 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.